{"id":502246,"date":"2020-08-14T13:38:01","date_gmt":"2020-08-14T13:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=502246"},"modified":"2020-08-14T13:38:01","modified_gmt":"2020-08-14T13:38:01","slug":"biliary-tract-cancers-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/biliary-tract-cancers-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_502246.html","title":{"rendered":"Biliary Tract Cancers Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Biliary Tract Cancers Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Biliary Tract Cancers Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on<strong> &#8220;Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast-2030&#8221;.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s<strong> &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\" target=\"_blank\">Biliary Tract Cancers (BTCs) &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/a>&#8221;&nbsp;<\/strong>report delivers an in-depth understanding of the Biliary Tract Cancers (BTCs), historical and forecasted epidemiology as well as the Biliary Tract Cancers (BTCs) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA) with 4,471 cases, followed by Italy and the United Kingdom.<\/li>\n<li>As per DelveInsight insights, the incidence rate varied based on type specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some are stable cases.<\/li>\n<li>DelveInsight&rsquo;s assessment based on the recent studies suggests that overall 37% of the CCA cases belongs to US in the 7M for the study period of 2017.<\/li>\n<li>Spain had the lowest incident population. As per our estimates, Japan had 4,287 incident cases of Cholangiocarcinoma (CCA) in 2017.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market\">https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Biliary Tract Cancers (BTCs), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Biliary Tract Cancers (BTCs) epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Biliary Tract Cancers (BTCs) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Biliary Tract Cancers (BTCs) market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Biliary Tract Cancers (BTCs) market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key companies Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Agios Pharmaceuticals<\/li>\n<li>Incyte Corporation<\/li>\n<li>Delcath Systems<\/li>\n<li>QED Therapeutics<\/li>\n<li>Nucana<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market\">https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\" target=\"_blank\">Biliary Tract Cancer (BTC)<\/a>, <\/strong>also known as Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation.<\/p>\n<p style=\"text-align: justify;\">The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder.<\/p>\n<p style=\"text-align: justify;\">Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET and the EGFR family members are key signaling pathways in cholangiocarcinogenesis.<\/p>\n<p style=\"text-align: justify;\">It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA) but are now considered distinct entities based upon differences in their tumor biology and management.<\/p>\n<p style=\"text-align: justify;\">According to the ICD 10 classification of the disease, CCA is coded as intrahepatic bile duct carcinoma (C22.1), extrahepatic bile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of biliary tract (C24.8) (includes malignant neoplasm of biliary tract whose point of origin cannot be classified to any one of the categories); or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Whole genome sequencing performed by the International Cancer Genome Consortium revealed distinct mutations that affect prognosis. Broadly, BTCs have clusters of mutations in known oncogenes (KRAS, p53, ERBB2\/HER2\/NEU) and tumor suppressor genes (SMAD-4, BCL-2, p16, and p53).<\/p>\n<p style=\"text-align: justify;\">Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ivosidenib<\/li>\n<li>Pemigatinib<\/li>\n<li>Melphalan Hydrochloride<\/li>\n<li>Infigratinib<\/li>\n<li>Acelarin<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market\">https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Biliary Tract Cancers (BTCs)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Competitive Intelligence Analysis for Biliary Tract Cancers (BTCs)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Biliary Tract Cancers (BTCs): Market Overview at a Glance<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\"><strong>5. Biliary Tract Cancers (BTCs): Disease Background and Overview<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2. Sign and Symptoms&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3. Pathophysiology&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4. Risk Factors&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5. Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>6. Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Biliary Tract Cancers (BTCs) Epidemiology and Patient Population<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.1.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.2.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in France (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.5.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.6.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><strong>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1. Biliary Tract Cancers (BTCs) Treatment and Management<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2. Biliary Tract Cancers (BTCs) Treatment Algorithm&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>9. Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Key Endpoints of Biliary Tract Cancers (BTCs) Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Marketed Products<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>12. Emerging Therapies<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><strong>13. Biliary Tract Cancers (BTCs): Seven Major Market Analysis<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Biliary Tract Cancers (BTCs) Market Size in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\"><strong>14. Attribute analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. 7MM: Market Outlook<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.1. Biliary Tract Cancers (BTCs) Total Market Size in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1. Biliary Tract Cancers (BTCs) Total Market Size in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.1. Biliary Tract Cancers (BTCs) Total Market Size in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.1. Biliary Tract Cancers (BTCs) Total Market Size in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.1. Biliary Tract Cancers (BTCs) Total Market Size in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.1. Biliary Tract Cancers (BTCs) Total Market Size in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.2. Biliary Tract Cancers (BTCs) Total Market Size in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><strong>16. Access and Reimbursement Overview of Biliary Tract Cancers (BTCs)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Market Drivers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Market Barriers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>21. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>23. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for detailed TOC:<\/strong><strong>&nbsp;https:\/\/www.delveinsight.com\/sample-request\/biliary-tract-cancers-btcs-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=biliary-tract-cancers-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=biliary-tract-cancers-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast-2030&#8221; DelveInsight has launched a new report on &#8220;Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast-2030&#8221;. &nbsp; DelveInsight&#8217;s &#8220;Biliary Tract Cancers (BTCs) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;&nbsp;report delivers an &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/biliary-tract-cancers-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_502246.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-502246","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=502246"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502246\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=502246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=502246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=502246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}